N/A N=4,561 Influenza Resistance Information Study
Influenza
Primary: Number of Participants With Genotypic Resistance — 44; 1; 0; 2 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=326 High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza
Influenza · Avian Influenza · Severe Influenza
Primary: Proportion of All Participants Negative for Viral RNA on Day 5 — 115; 105 participants — p=0.42
N/A N=558 Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
Influenza, Human
Primary: Percentage of Participants With Virus Detectable by Quantitative PCR (qPCR) in Nasopharyngeal (NP) Swabs at Day 3 -- Team Collected Samples — 99; 131 Participants…
Phase 3 N=7,250 Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection
Influenza
Primary: Efficacy of an Investigational Vero Cell-derived Influenza Vaccine to Prevent Infection With an Influenza Virus That is Antigenically Similar to One of the Three Strains…
N/A N=178 Evaluating Modes of Influenza Transmission Observational Study of Community Acquired Influenza
Influenza Virus Infection Transmission in Humans
Primary: Viral Copy Number in 30-minute Exhaled Breath Sample — 38,000; 12,000 Fine aerosol RNA copy number
Phase 4 N=28 Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)
Influenza
Primary: Count of Participants From Each Arm Who Received Influenza Vaccine — 1; 3; 11; 13 Participants
Phase 1 N=95 Interferon as a Mucosal Adjuvant for Influenza Vaccine Given Intranasally
Influenza
Primary: Antibody Responses in Nasal Secretions to Influenza A/H1N1 and A/H3N2 at 14 Days After Intranasal Immunization. — 3; 3; 5; 0 Participants
Phase 2 N=116 Statin Therapy in Acute Influenza
Influenza
Primary: Change in Inflammatory Markers From Time Zero to 72 Hours — 2.4; 3.46; 0.91; 0.57 pg/ml — p=0.611
Phase 4 N=165 Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders
Plasma Cell Neoplasm
Primary: Seroprotection Based on Hemagglutination Antibody Inhibition (HAI) — 32; 22 Participants
Phase 4 N=13 The Human Mucosal Immune Responses to Influenza Virus (SLVP026)
Influenza
Primary: Number of Participants From Each Arm Who Received Influenza Vaccine — 3; 8 Participants
N/A N=75 Cell Mediated Immunity Against RSV and Influenza in a Human Experimental Challenge
Respiratory Syncytial Virus Infections · Influenza, Human
Primary: Total Symptom Score — 29.25; 17.50; 11.00; 13.00 score on a scale
N/A N=93 Rapid Flu Tests in Travelers With Fever
Influenza
Primary: Cost for the Medical Management of Patients — 581; 661 USD
Phase 4 N=125 Development of Childhood Anti-Influenza Immunity
Influenza · Influenza Immunisation
Primary: Frequency of CD4 T Cells With a Given Functional Potential — 0.70; 0.55; 0.52; 0.38 Percentage
Phase 2 N=385 Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population
Influenza · Influenza Vaccines
Primary: Serum Haemagglutination-inhibition (HI) Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2) — 24.4; 15.6; 14.6; 9.8 Titer
Phase 2 N=65 Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A
Influenza A H3N2 · Influenza A H1N1
Primary: Frequency Counts and Percentage of Subjects With Adverse Events — 6; 6; 1; 3 Participants
N/A N=133 Influenza Immunity in Children
Influenza
Primary: Mean Percent of IFNg+ CD69+ CD4 T Cells Between Acute (H3N2) Infected and Vaccinated Subjects — .010; 0.003; 0.009; 0.002 percentage of T cells — p=0.005
Phase 3 N=3,670 Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)
Influenza
Primary: Number of Subjects Developing Influenza Infection, as Confirmed by Viral Culture and Typing of Naso-pharyngeal Specimens — 35; 62 Participants
Phase 4 N=78 The Influence of Chronic CMV Infection on Influenza Vaccine Responses
Cytomegalovirus Infections · Influenza
Primary: Number of Participants From Each Arm Who Received Influenza Vaccine — 33; 37; 8 Participants
N/A N=1,918 FluSAFE: Flu SMS Alerts to Freeze Exposure
Influenza · Acute Respiratory Infection · Influenza-like Illness
Primary: Number of Laboratory-confirmed Influenza Infections — .22; .14 infections
Phase 3 N=120 Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the Southern Hemisphere 2015 Season
Influenza
Primary: the Serum Antihemagglutinin Antibody Titers and the Derived Parameters Defined in the Committee for Medicinal Products for Human Use (CHMP) Note for Guidance on…
Phase 2 N=150 Study of an Investigational Monoclonal Antibody, VIS410, in Subjects With Uncomplicated Influenza A
Influenza
Primary: Assess the Safety and Tolerability of a Single IV Dose of VIS410 in Participants With Uncomplicated Influenza Infection — 57.1; 34.7; 45.9; 26.0 percentage of participants
N/A N=30 The Effects of Preceding LPS Administration on the Fluenz-induced Immune Response
Innate Immune Response · Immune Tolerance
Primary: Peak Levels of Interferon Gamma-induced Protein 10 (IP-10) in Nasal Wash Fluid — 2000; 1900 pg/mL
Phase 2 N=79 Influenza Virus Vaccine Plus Vitamin A and D Supplements for Prevention of Respiratory Virus Infections in Children
Healthy Participants
Primary: Percentage of Participants With Positive Responses in Virus-specific Antibody in Sera — 80; 75; 100; 100 percentage of participants
Phase 1 N=45 Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine
Influenza
Primary: Safety - Serious Adverse Event — 0; 0; 0 SAEs
Phase 2 N=630 Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications
Influenza
Primary: Percentage of Participants With Virus Detectable by Quantitative PCR (qPCR) in Nasopharyngeal (NP) Swabs — 40; 50 percentage of participants analyzed — p=0.046
Phase 3 N=329 Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza
Influenza A · Influenza B
Primary: Number of Patients in Each of 6 Clinical Status Categories on Day 7 — 3; 2; 6; 11 Participants — p=.33
N/A N=131 Mechanisms of Severe Acute Influenza Consortium (MOSAIC)
Influenza
Primary: Number of Patients With Clinical Phenotype Presenting Also a Sequential Activation of Immune/Infammatory Pathways. — 131 Participants
N/A N=411 Evaluation of Moderate to Severe Influenza Outcomes in Children
Influenza · Otitis Media · Lower Resp Tract Infection
Primary: Hospitalization — 26; 2 Participants
N/A N=1,849 Comparison of Epidemiology and Clinical Outcomes of Influenza A & B Cases in Manitoba, Canada
Influenza
Primary: Age Adjusted Percentage of Participants With a Physician Visit Due to Any Diagnosis Within 30 Days of the Index Date of the Confirmed Influenza A and B Cases in the…
Phase 3 N=37 A Study on Emergence of Resistance With Oseltamivir (Tamiflu) in Participants With Seasonal Influenza
Influenza
Primary: Percentage of Participants Excreting Resistant Virus — 26.3; 35.3 percentage of participants — p=0.825